Compare Cognizant Technology Solutions Corp (CTSH) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Gilead Sciences, Inc. — how do they compare? Cognizant Technology Solutions Corp trades at $59.82 (market cap $27.03B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 6.7× Cognizant Technology Solutions Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Gilead Sciences, Inc. for 111 Days on average.
| CTSH | GILD | |
|---|---|---|
Market Cap | $27.03B | $182.40B |
Volume | 9,883,888 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $86.70 | $155.80 |
52-Week Low | $38.73 | $116.74 |
Typical Hold Time | 57 Days | 111 Days |
Enterprise Value | $28.08B | $205.46B |
Dividend Yield | 2.2% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 12.25 and EV/EBITDA of 6.52, while maintaining solid profitability with 10.26% net margin. Recent news highlights the company's AI transformation initiatives and recognition as a top employer, though Q2 2026 earnings missed expectations.
CTSH presents a compelling value opportunity with strong fundamentals and analyst consensus target of $64.25 (12.6% upside). Risks include IT spending pressures from AI disruption and competitive threats. The upcoming Q3 2026 earnings report on October 29, 2026 will be critical for validating the company's growth trajectory amid industry headwinds.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
